• العربية
  • 简体中文
  • Français
  • Português
  • Русский
  • Español

James Lind LibraryThe James Lind Library
Illustrating the development of fair tests of treatments in health care

  • Home
  • About the Library
  • Topics
  • Essays
  • Records
  • Articles

Goldacre B (2012)

Bad Pharma: how drug companies mislead doctors and harm patients. London: Fourth Estate.

Title page(s)

Goldacre_2012_tp1 Goldacre_2012_tp2 Goldacre_2012_tp3

Key passage(s)

Goldacre_2012_kp1 Goldacre_2012_kp3 Goldacre_2012_kp4 Goldacre_2012_kp5 Goldacre_2012_kp6 Goldacre_2012_kp7 Goldacre_2012_kp8 Goldacre_2012_kp9 Goldacre_2012_kp10

RELEVANT TOPICS

  • Reporting bias

All topics

  • Individual patient data
  • Pre-clinical
  • Fair tests of treatments
    • The need to address treatment uncertainties
      • Principles of Testing
    • Treatment comparisons are essential
      • Dramatic effects
      • Placebo effects
    • Treatment comparisons must be fair
  • Biases
    • Design bias
    • Allocation bias
      • N-of-1 crossover
      • Cluster allocation
      • Crossover tests
      • Factorial design
    • Co-intervention bias
    • Observer bias
      • Double dummy
    • Analysis bias
    • Biases in judging unanticipated possible effects
    • Reporting bias
    • Biases in systematic reviews
    • Researcher/sponsor bias and fraud
  • The play of chance
    • Recording and interpreting numbers
    • Quantifying uncertainty
    • Using meta-analysis
  • Bringing it all together for the benefit of patients and the public
    • Improving reports of research
    • Preparing and maintaining systematic reviews
    • Using the results of research

BROWSE

Topics
Essays
Records
Articles

ABOUT

What is a fair test?
About the Library
Building the Library
Using the Library

COPYRIGHT

Where not otherwise indicated, material in the James Lind Library is licensed under a Creative Commons Attribution 4.0 International License.

FEEDBACK

Contact us

We welcome your suggestions for the design or content of the Library

Website by Minervation Ltd, supported by the James Lind Initiative and the Presidential Fund of the Swiss National Science Foundation.